Message #10 From:
Stock News Bot Date: January 8, 2007 06:31:00 AM
PMED News Paradigm Medical Industries Announces Operations and Sales Management Reorganization
SALT LAKE CITY--(BUSINESS WIRE)--Paradigm Medical Industries, Inc. (OTCBB: PMED.OB/PMEDW.OB), a leading
innovative producer of ultrasound devices for the ophthalmic and medical
industries, disclosed today a major reorganization of its global
operations and sales management, effective immediately.
Al Franklin joins Paradigm Medical as Vice-President Domestic Sales,
replacing Michael Austin, who has left the Company. Mr. Franklin has
been associated with the ophthalmic industry for the last 25 years,
previously serving at Pfizer and Pharmacia.
Christina O’Connor has been promoted to
Vice-President International Sales. Ms. O’Connor
joined Paradigm Medical in 2004 as Regional Sales Representative, and
has been serving as International Manager for Europe and the Middle
East. Along with global sales management responsibility Ms. O’Connor
will continue to direct the European and Middle East distribution
channels.
Deborah Petric has joined Paradigm Medical as Director of Regulatory
Affairs and Quality Assurance, replacing Thomas Martin, who has left the
Company. Ms. Petric has served in similar positions at Amerace
Laboratories, Sorenco Laboratories, and Nature’s
Ways Products.
Julio Maximo has been promoted to Vice-President Operations. Mr. Maximo
joined Paradigm Medical as an Ultrasound technician in 2001, and was
promoted to Ultrasound engineer in 2002. Mr. Maximo took charge of
production in October 2004, and was named Director of Production in
February 2005. A native of Brazil, Mr. Maximo earned a degree in
Electrical Engineering from FIEC.
Chad Scott has been promoted to International Territory Manager for Asia
with similar responsibilities for portions of the Western region of the
U.S. Mr. Scott joined Paradigm Medical in 2003 as manager of the service
department and most recently has been involved with sales, marketing and
customer relations.
“Our Company now has a strong, experienced,
and dedicated operations management and sales management group that will
enable us to maximize our expanded high-value-added, global-oriented
product portfolio,” said Paradigm Medical’s
Chief Executive Officer, Raymond Cannefax. “We
believe the rigorous restructuring and reorganization efforts the
Company has implemented during the last 12 months will be reflected in
excellent results and returns for Paradigm Medical in 2007 and the
foreseeable future.”
Mr. Cannefax also updated Paradigm Medical’s
recent activities. “We had an excellent
exhibit at the recent American Academy of Ophthalmology (AAO)
Convention. Several new products were introduced and have already
generated sales. There has been especially strong global interest in the
new LD700 Visual Field Scanner (VFS) Perimeter, which has become our
third-generation perimeter, and which has already received U.S. Food and
Drug Administration and European CE Mark regulatory approval.”
Perimeters are used to measure visual field loss caused by glaucoma or
other diseases. Perimeters have become a standard care in the protection
and monitoring of glaucoma and macular degeneration worldwide. The
Company’s LD400 VFS is the only perimeter to
utilize the patented “kinetic fixation”
technology along with fast-threshold exam strategies.
Paradigm Medical Industries, Inc. (Salt Lake City, UT), currently
develops, manufactures and markets high-tech, proprietary diagnostic
equipment and consumable products for the medical industry. The Company
is a leading developer of Ultrasound devices, and has been dubbed “The
UMB Company” (Ultrasound BioMicroscope).
Contact us at 801-977-8970 or visit us at www.paradigm-medical.com.
This press release contains statement that, if not verifiable historic
fact, may be viewed as forward-looking statement that could predict
future events and outcomes with respect to Paradigm and its business.
The predictions embodied in these statements will involve risk and
uncertainties and, accordingly, actual results may differ significantly
from the results discussed or implied in such forward-looking statements.
